Brought to you by 
FoxHollow and Merck study cardiac biomarkers
16 Nov 2022
Executive Summary
FoxHollow Technologies (cardiovascular devices) and Merck have entered into a three-year pharmacogenomics deal to analyze atherosclerotic plaque and identify genes and proteins associated with cardiovascular disease progression.
Deal Industry
- Pharmaceuticals
-
Medical Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Surgical Equipment & Devices
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Technologies
- Genomics-Proteomics
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
FoxHollow and Merck study cardiac biomarkers
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice